ALKS 37 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid-induced Constipation
Conditions
Opioid-induced Constipation
Trial Timeline
Aug 1, 2011 → Apr 1, 2012
NCT ID
NCT01382797About ALKS 37 + Placebo
ALKS 37 + Placebo is a phase 2 stage product being developed by Alkermes for Opioid-induced Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT01382797. Target conditions include Opioid-induced Constipation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01418092 | Phase 2 | Completed |
| NCT01382797 | Phase 2 | Completed |
Competing Products
20 competing products in Opioid-induced Constipation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Approved | 85 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| Naloxegol + Placebo Oral Capsule | AstraZeneca | Phase 2 | 52 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Methylnaltrexone bromide + Placebo | Pfizer | Phase 2 | 51 |